Market Place
Sourcing Support
Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome
18 Jul 2022 //
GLOBENEWSWIRE
Ultragenyx granted go-ahead to up doses for Angelman therapy
06 Jan 2022 //
STREETINSIDER
FDA Lifts Clinical Hold from Ultragenyx-GeneTx`s Angelman syndrome candidate
28 Sep 2021 //
ENDPTS
GeneTx and Ultragenyx get UK approval for Angelman syndrome trial
11 Jun 2021 //
CLINICAL TRAILS ARENA
GeneTx and Ultragenyx Receive Clearance from Health Canada Clinical of GTX-102
18 May 2021 //
GLOBENEWSWIRE
Gene therapy for autism-linked condition weakened legs, robbing two people
05 Nov 2020 //
SCIENCEMAG
GeneTx and Ultragenyx Announce Positive Interim Ph 1/2 Data on INVG GTX-102
26 Oct 2020 //
GLOBENEWSWIRE
GeneTx and Ultragenyx Announce GTX-102 Granted Fast Track Designation
04 May 2020 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.